• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

冻干粉可以改善高脂肪饮食诱导的非酒精性脂肪肝。

Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease.

机构信息

Department of Traditional Chinese Medicine, Hebei North University, Zhangjiakou 075000, Hebei Province, China.

Department of Gastroenterology, People's Hospital of Changshou District, Chongqing 401220, China.

出版信息

World J Gastroenterol. 2019 Jun 28;25(24):3056-3068. doi: 10.3748/wjg.v25.i24.3056.

DOI:10.3748/wjg.v25.i24.3056
PMID:31293341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6603807/
Abstract

BACKGROUND

Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease worldwide. However, to date, there is no ideal therapy for this disease.

AIM

To study the effects of Si-Ni-San freeze-dried powder on high fat diet-induced NAFLD in mice.

METHODS

Twenty-four male C57BL/6 mice were randomized into three groups of eight. The control group (CON) was allowed access to a normal chow diet. The high fat diet group (FAT) and Si-Ni-San group (SNS) were allowed access to a high fat diet. The SNS group was intragastrically administered Si-Ni-San freeze-dried powder (5.0 g/kg) once daily, and the CON and FAT groups were intragastrically administered distilled water. After 12 wk, body weight, liver index, visceral fat index, serum alanine aminotransferase (ALT), portal lipopoly-saccharide (LPS), liver tumor necrosis factor (TNF)-α and liver triglycerides were measured. Intestinal microbiota were analyzed using a 16S r DNA sequencing technique.

RESULTS

Compared with the FAT group, the SNS group exhibited decreased body weight, liver index, visceral fat index, serum ALT, portal LPS, liver TNF-α and liver triglycerides ( < 0.05). Intestinal microbiota analysis showed that the SNS group had different bacterial composition and function compared with the FAT group. In particular, genus was a bacterial biomarker of SNS group samples.

CONCLUSION

The beneficial effects of Si-Ni-San freeze-dried powder on high fat diet-induced NAFLD in mice may be associated with its anti-inflammatory and changing intestinal microbiota effects.

摘要

背景

非酒精性脂肪性肝病(NAFLD)是一种常见的慢性肝脏疾病,在全球范围内都很普遍。然而,迄今为止,针对这种疾病还没有理想的治疗方法。

目的

研究思尼散冻干粉对高脂饮食诱导的小鼠非酒精性脂肪性肝病的影响。

方法

将 24 只雄性 C57BL/6 小鼠随机分为三组,每组 8 只。对照组(CON)给予普通饲料。高脂饮食组(FAT)和思尼散组(SNS)给予高脂饮食。SNS 组每日给予思尼散冻干粉(5.0 g/kg)灌胃,CON 和 FAT 组给予蒸馏水灌胃。12 周后,测量体重、肝指数、内脏脂肪指数、血清丙氨酸氨基转移酶(ALT)、门脉脂多糖(LPS)、肝肿瘤坏死因子(TNF)-α和肝甘油三酯。采用 16S rDNA 测序技术分析肠道微生物群。

结果

与 FAT 组相比,SNS 组的体重、肝指数、内脏脂肪指数、血清 ALT、门脉 LPS、肝 TNF-α和肝甘油三酯降低(<0.05)。肠道微生物群分析显示,SNS 组与 FAT 组的细菌组成和功能存在差异。特别是,属是 SNS 组样本的细菌生物标志物。

结论

思尼散冻干粉对高脂饮食诱导的小鼠非酒精性脂肪性肝病的有益作用可能与其抗炎和改变肠道微生物群的作用有关。

相似文献

1
Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease.冻干粉可以改善高脂肪饮食诱导的非酒精性脂肪肝。
World J Gastroenterol. 2019 Jun 28;25(24):3056-3068. doi: 10.3748/wjg.v25.i24.3056.
2
Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development.不同饮食对肠道微生物群及非酒精性脂肪性肝病发展的影响。
World J Gastroenterol. 2016 Aug 28;22(32):7353-64. doi: 10.3748/wjg.v22.i32.7353.
3
Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.参令白术散对高脂饮食诱导的非酒精性脂肪肝大鼠肠道微生物群的影响。
Biomed Pharmacother. 2018 Jun;102:1025-1036. doi: 10.1016/j.biopha.2018.03.158. Epub 2018 Apr 5.
4
Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.用绞股蓝缓解大鼠非酒精性脂肪肝病过程中肠道微生物群的结构调节。
BMC Complement Med Ther. 2020 Feb 5;20(1):34. doi: 10.1186/s12906-020-2835-7.
5
Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.中药方剂对非酒精性脂肪肝的调控作用。
World J Gastroenterol. 2019 Sep 14;25(34):5105-5119. doi: 10.3748/wjg.v25.i34.5105.
6
[Effect of Modified Xiaoyao Powder on intestinal barrier and intestinal flora in mice with metabolic associated fatty liver disease based on "gut-liver axis"].基于“肠-肝轴”探讨加味逍遥散对代谢相关脂肪性肝病小鼠肠道屏障及肠道菌群的影响
Zhongguo Zhong Yao Za Zhi. 2024 Aug;49(16):4499-4509. doi: 10.19540/j.cnki.cjcmm.20240506.401.
7
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.丁酸钠通过改善肠道微生物群和胃肠道屏障减轻高脂饮食诱导的小鼠脂肪性肝炎。
World J Gastroenterol. 2017 Jan 7;23(1):60-75. doi: 10.3748/wjg.v23.i1.60.
8
Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.四妙方通过调节肝脏脂质代谢和肠道微生物群来减轻非酒精性脂肪性肝病。
Phytomedicine. 2021 May;85:153544. doi: 10.1016/j.phymed.2021.153544. Epub 2021 Mar 10.
9
Lingguizhugan decoction attenuates diet-induced obesity and hepatosteatosis gut microbiota.灵龟护肝汤减轻饮食诱导的肥胖和肝脂肪变性与肠道微生物群。
World J Gastroenterol. 2019 Jul 21;25(27):3590-3606. doi: 10.3748/wjg.v25.i27.3590.
10
Seabuckthorn () Freeze-Dried Powder Protects against High-Fat Diet-Induced Obesity, Lipid Metabolism Disorders by Modulating the Gut Microbiota of Mice.沙棘()冻干粉通过调节小鼠肠道微生物群预防高脂饮食诱导的肥胖和脂代谢紊乱。
Nutrients. 2020 Jan 20;12(1):265. doi: 10.3390/nu12010265.

引用本文的文献

1
Sini san regulates intestinal flora and short-chain fatty acids to ameliorate hepatocyte apoptosis and relieve CCl-induced liver fibrosis in mice.四逆散通过调节肠道菌群和短链脂肪酸来改善小鼠肝细胞凋亡并减轻四氯化碳诱导的肝纤维化。
Front Pharmacol. 2024 Aug 30;15:1408459. doi: 10.3389/fphar.2024.1408459. eCollection 2024.
2
Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway.思尼散通过 AMPK/SIRT1 通路减少代谢相关脂肪性肝病大鼠肝内脂质沉积。
Drug Des Devel Ther. 2023 Oct 3;17:3047-3060. doi: 10.2147/DDDT.S417378. eCollection 2023.
3
Sinisan ameliorates colonic injury induced by water immersion restraint stress by enhancing intestinal barrier function and the gut microbiota structure.

本文引用的文献

1
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理:美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
2
Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study.中药方剂四逆散对慢性束缚应激诱导的非酒精性脂肪性肝病的影响:一项大鼠研究
BMC Complement Altern Med. 2017 Apr 7;17(1):203. doi: 10.1186/s12906-017-1707-2.
3
Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
四逆散通过增强肠道屏障功能和肠道微生物群落结构来改善水浸束缚应激引起的结肠损伤。
Pharm Biol. 2023 Dec;61(1):598-609. doi: 10.1080/13880209.2023.2191643.
4
Intestinal flora: A new target for traditional Chinese medicine to improve lipid metabolism disorders.肠道菌群:中药改善脂质代谢紊乱的新靶点。
Front Pharmacol. 2023 Mar 1;14:1134430. doi: 10.3389/fphar.2023.1134430. eCollection 2023.
5
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Bunge.中药治疗非酒精性脂肪性肝病的治疗潜力:一种有前景的药物 远志。 (注:这里的“Bunge”可能是某种植物的拉丁名,比如远志属植物,具体需结合上下文准确判断,这里暂且直译为“远志” )
Acta Pharm Sin B. 2022 Sep;12(9):3529-3547. doi: 10.1016/j.apsb.2022.05.001. Epub 2022 May 11.
6
Interaction Mechanisms Between Major Depressive Disorder and Non-alcoholic Fatty Liver Disease.重度抑郁症与非酒精性脂肪性肝病之间的相互作用机制
Front Psychiatry. 2021 Dec 13;12:711835. doi: 10.3389/fpsyt.2021.711835. eCollection 2021.
7
Network Pharmacology-Based Analysis on the Potential Biological Mechanisms of Sinisan Against Non-Alcoholic Fatty Liver Disease.基于网络药理学的四逆散抗非酒精性脂肪性肝病潜在生物学机制分析
Front Pharmacol. 2021 Aug 27;12:693701. doi: 10.3389/fphar.2021.693701. eCollection 2021.
8
Network Pharmacological Analysis and Experimental Validation of the Mechanisms of Action of Si-Ni-San Against Liver Fibrosis.四逆散抗肝纤维化作用机制的网络药理学分析与实验验证
Front Pharmacol. 2021 Jul 1;12:656115. doi: 10.3389/fphar.2021.656115. eCollection 2021.
9
Role of gut microbiota via the gut-liver-brain axis in digestive diseases.肠道微生物群通过肠-肝-脑轴在消化系统疾病中的作用。
World J Gastroenterol. 2020 Oct 28;26(40):6141-6162. doi: 10.3748/wjg.v26.i40.6141.
10
Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science.针对非酒精性脂肪肝治疗的肠道-肝脏轴和脂肪组织-肝脏轴的中草药:古代智慧与现代科学。
Front Endocrinol (Lausanne). 2020 Sep 30;11:572729. doi: 10.3389/fendo.2020.572729. eCollection 2020.
益生菌可能通过恢复肠道微生物群落结构和改善肠道内毒素血症来延缓非酒精性脂肪性肝病的进展。
Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176.
4
Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.丁酸钠通过改善肠道微生物群和胃肠道屏障减轻高脂饮食诱导的小鼠脂肪性肝炎。
World J Gastroenterol. 2017 Jan 7;23(1):60-75. doi: 10.3748/wjg.v23.i1.60.
5
Oscillospira and related bacteria - From metagenomic species to metabolic features.颤螺菌属及相关细菌——从宏基因组物种到代谢特征
Environ Microbiol. 2017 Mar;19(3):835-841. doi: 10.1111/1462-2920.13658. Epub 2017 Feb 3.
6
Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development.不同饮食对肠道微生物群及非酒精性脂肪性肝病发展的影响。
World J Gastroenterol. 2016 Aug 28;22(32):7353-64. doi: 10.3748/wjg.v22.i32.7353.
7
The gut microbiota and metabolic disease: current understanding and future perspectives.肠道微生物群与代谢疾病:当前的认识和未来展望。
J Intern Med. 2016 Oct;280(4):339-49. doi: 10.1111/joim.12508. Epub 2016 Apr 12.
8
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
Diabetologia. 2016 Jun;59(6):1121-40. doi: 10.1007/s00125-016-3902-y.
9
Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.采用综合宏基因组学方法分析小儿非酒精性脂肪肝和肥胖患者的肠道微生物组。
Hepatology. 2017 Feb;65(2):451-464. doi: 10.1002/hep.28572. Epub 2016 Jun 2.
10
Modulation of Gut Microbiota by Berberine Improves Steatohepatitis in High-Fat Diet-Fed BALB/C Mice.黄连素对肠道微生物群的调节改善了高脂饮食喂养的BALB/C小鼠的脂肪性肝炎。
Arch Iran Med. 2016 Mar;19(3):197-203.